pharmaceutical investing Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial
pharmaceutical investing Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
Resource Expansion Drilling Confirms 3,000 metres of New Uranium Trends with Best Drill Hole of 1.4 GT over 7.6 metres